
(NASDAQ: KZIA) announced positive news this morning from its phase 1 clinical trial. Shares are $2.14 and there are 3400 trades with 727k in volume. The stock has a 52-week high of $12.28 is currently up 22%
http://archive.fast-edgar.com/20220805/AW2ZE22EZC2R22Z2222R2CYQG3ASZZ22XI42/